MicroRNA dysregulation in colorectal cancer: a clinical perspective by Dong, Y et al.
Minireview
MicroRNA dysregulation in colorectal cancer: a clinical perspective
Y Dong
1,2, WKK Wu
1,C WW u
1, JJY Sung
1,JY u *,1 and SSM Ng*,1,2
1Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital,
The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China;
2Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong
Kong, Shatin, NT, Hong Kong, China
Recent researches have shed light on the biological importance of microRNAs (miRNAs) in colorectal cancer (CRC) genesis,
progression and response to treatments. The potential utility of miRNAs in the preclinical stage have been explored and investigated.
In this review, we explored the literature and reviewed the cutting edge progress in the discovery of noninvasive plasma and faecal
miRNAs for CRC early diagnosis, as well as their measurability and predictability. We also discussed the utility of miRNAs as novel
prognostic and predictive markers, and their association with CRC clinical phenotypes including recurrence, metastasis and
therapeutic outcomes. Finally, we summarised miRNA-related single-nucleotide polymorphisms and their potential influence on
sporadic CRC susceptibility and therapeutic response. In conclusion, the use of miRNAs as biomarker for CRC is still in its infancy and
need further characterisation and evaluation.
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MicroRNAs (miRNAs), a class of highly conserved B22-nucleo-
tides single-stranded RNAs, can act as trans-acting factors that
suppress translation or induce messenger RNA (mRNA) degrada-
tion of target genes (Bartel, 2004). A spectrum of dysregulated
miRNAs was identified to be associated with colorectal cancer
(CRC) genesis, progression and therapeutic response. Herein, we
summarise recent findings and discuss the potential value of
miRNAs as biomarkers for CRC diagnosis, prognosis and
susceptibility.
miRNAs AS DIAGNOSTIC MARKERS
Approximately 1.23 million individuals worldwide will develop
CRC and 0.6 million people will die of it annually (Ferlay et al,
2010). Fortunately, the mortality and morbidity have modestly
declined and CRC has become a preventable disease if pre-
neoplastic lesions can be detected with modern screening methods
(Lieberman, 2009). Among the available screening approaches,
colonoscopy is recommended as the gold standard for high-risk
people; however, its invasive nature and expensive cost have
hampered the worldwide application. This setting provides the
foundation for defining new biomarkers in blood and stool, which
can offer more acceptable and practical benefits.
PLASMA miRNAs AS DIAGNOSTIC MARKERS
Surprisingly high concentration of miRNAs is discovered in highly
stable, cell-free form in the peripheral blood (Mitchell et al, 2008).
Circulating miRNAs are packed in complexes, either called
exosomes or microvesicles, and released by normal and tumour
cells through unknown mechanisms. Emerging evidence has
indicated that such external miRNAs are also involved in cell-to-
cell signal transduction and genetic information exchange (Kosaka
et al, 2010). Given that aberrantly expressed miRNAs vary among
different tumour types and some of them are secreted into blood
(Mitchell et al, 2008), circulating miRNAs can potentially serve as
noninvasive markers for CRC detection.
We have previously discovered that miR-17-3p and miR-92a
(previously named miR-92), both belonging to the miR-17-92
cluster, were significantly elevated in plasma and CRC tissues, but
reduced in the postoperative samples when compared with
preoperative samples. These data support the idea that CRC cells
can release aberrantly expressed miRNAs into the circulatory
system. Furthermore, promising discriminatory power of the two
miRNAs was verified in an independent larger cohort: at a cut-off
value of 3.6 for miR-17-3p (relative expression in comparison with
RNU6B), the sensitivity was 64% and the specificity was 70%; at a
cut-off value of 240 for miR-92a, the sensitivity was 89% and the
specificity was 70% (Table 1). In addition, miR-92a could
distinguish CRC from other gastrointestinal cancers and inflam-
matory bowel diseases (Ng et al, 2009). Diagnostic potential of
miR-92a was further verified by Huang et al. They confirmed that
miR-92a was significantly increased in CRC plasma compared with
healthy control, and the sensitivity and specificity were consistent
with our previous study (Table 1). It was also reported that miR-
92a could distinguish advanced adenoma from normal control,
with a sensitivity of 64.9% and a specificity of 81.4%, whereas its
expression levels were not correlated with tumour-node-metastasis
(TNM) stages (Ng et al, 2009; Huang et al, 2010).
Tumour-derived plasma miR-29a is another potential CRC
diagnostic marker. It was demonstrated that plasma miR-29a could
distinguish CRC and advanced adenoma from normal group with
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respectively (Table 1). Further studies indicated that the level of
miR-29a was significantly increased in CRC compared with
adenoma, and that its expression was associated with more
advanced TNM stages (Huang et al, 2010).
Employing high-throughput transcriptomic sequencing techni-
que, Chen et al (2008) found that the serum miRNA expression
profiles of CRC and healthy controls were significantly different: 69
miRNAs were only detected in CRC but not in the control group.
Nevertheless, it is most likely that only a minor portion of these
dysregulated miRNAs can be finally developed into CRC-specific
markers, since roughly 80% of the aberrantly expressed miRNAs
are also present in the serum of lung cancer patients (Chen et al,
2008). It is possible that common carcinogenesis-related miRNAs
are shared by different types of tumours or it is merely a tumour-
induced ‘systemic reaction’ generated from other sources, such as
immune cells. If the latter is the case, future studies should
cautiously verify the applicability of a single plasma miRNA, or the
use of a combination of multiple plasma miRNAs for specific CRC
diagnosis should be recommended.
In previous studies, SYBR green-based real-time polymerase
chain reaction (PCR) was generally adopted to detect the presence
of miRNA. However, this method has a lower specificity and
causes high false-positive and false-negative rates in diagnosis.
Recently, Kroh et al (2010) described an optimised method of
plasma/serum miRNA detection and data analysis. It is expected
that the improved protocol can increase the detection accuracy
and help to uncover novel miRNA markers in the plasma.
FAECAL miRNAs AS DIAGNOSTIC MARKERS
Stool-based test is widely adopted as noninvasive screening
methods for CRC diagnosis. Currently, the most commonly used
stool test for CRC screening is the guaiac-based faecal occult blood
test (FOBT). However, the test itself has some crucial limitations.
Owing to the irregular bleeding nature of colorectal tumours,
presence of red meat in digested residues, and other causes of
bleeding in the gastrointestinal tract, the specificity and sensitivity
of FOBT for CRC are relatively poor. Some advanced adenomas
with diameter larger than 1cm are missed by FOBT (Lieberman,
2009). Other stool-based detections depend on colonocytes that are
constantly exfoliated from the intestinal tract as well as from the
neoplastic site, which theoretically carry important genetic and
epigenetic information for subsequent testing, such as detection of
mutation genes or dysregulated mRNAs, proteins or miRNAs.
In contrast with the fast degradation of mRNA and protein,
endogenous miRNAs are packed and protected from RNase. They
are therefore more likely to be detected. Nonetheless, the stool
environment is much more complex and hostile than plasma, and
human RNA is expected to constitute o1% of totally stool RNA. In
this regard, several criteria, including measurability, reproduci-
bility and predictability, must be met if stool miRNAs have to be
developed as diagnostic markers. It is a ground-breaking attempt
that Ahmed et al (2009a) evaluated the feasibility of using miRNA
from faecal specimens as screening markers for CRC. They
developed a novel detection protocol including stool preparation,
stool miRNA extraction and quantitative analysis. Commercial
miRNA extraction kit is also available for stool miRNA purifica-
tion, which can yield total RNA of high quality and integrity for
further assays. Taqman-based quantitative real-time PCR is
performed for miRNA quantification, which can eliminate the
interference from food and intestinal bacteria. At present, this
analysis protocol is most widely adopted and further optimised by
other studies. For example, Koga et al (2010) used immuno-
magnetic beads conjugated with EpCAM monoclonal antibody to
isolate colonocytes from stool, rather than performing colonocytes
scrapping from the stool mucinous layer; several other studies
Table 1 miRNAs as potential diagnostic markers for CRC
miRNA
Sensitivity,
%
Specificity,
% AUC Sample size, n
Endogenous
control Remarks Reference
Plasma miRNA
miR-17-3p 64 70 CRC: 0.717
(95% CI: 0.63–0.80)
140 (90 CRC,
50 control)
RNU6B Upregulated in CRC plasma Ng et al (2009)
miR-92a 89 70 CRC: 0.885
(95% CI: 0.83–0.94)
140 (90 CRC,
50 control)
RNU6B Upregulated in CRC plasma,
could distinguish CRC from other
GI cancer and IBD, not associated
with TNM stages
Ng et al (2009)
miR-92a 84 71.2 CRC: 0.838
(95% CI: 0.775–0.900)
196 (100 CRC,
37 advanced
adenomas, 59 control)
miR-16 Upregulated in CRC plasma, not
associated with TNM stages
Huang et al
(2010)
64.9 81.4 Advanced adenomas:
0.749 (95% CI: 0.642–0.856)
miR-29a 69 89.1 CRC: 0.844
(95% CI: 0.786–0.903)
196 (100 CRC, 37
advanced adenomas,
59 control)
miR-16 Upregulated in CRC plasma,
associated with advanced
TNM stages
Huang et al
(2010)
62.2 84.7 Advanced adenomas:
0.769 (95% CI: 0.669–0.869)
Faecal miRNA
miR-92a 50 80 — 133 (59 CRC,
74 control)
Equal amount
of total RNA
Upregulated in stool
of CRC patients
Wu et al (2010)
miR-21 50 83 — 133 (59 CRC,
74 control)
Equal amount
of total RNA
Upregulated in stool
of CRC patients
Wu et al (2010)
miR-17-92
cluster
69.5 81.5 — 316 (197 CRC,
119 control)
U6 snRNA Upregulated in stool
of CRC patients
Koga et al (2010)
miR-135 46.2 95 — 316 (197 CRC,
119 control)
U6 snRNA Upregulated in stool
of CRC patients
Koga et al (2010)
Abbreviations: AUC¼area under the ROC curve; CI¼confidence interval; CRC¼colorectal cancer; GI cancer¼gastrointestinal cancer; IBD¼inflammatory bowel disease;
miRNA¼microRNA; snRNA¼small nuclear RNA; TNM¼tumour-node-metastasis.
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simpler method known as direct miRNA analysis, which analysed
extracellular miRNA in stool without RNA extraction has also been
recently developed (Link et al, 2010). It is necessary to compare
different methods in future studies and an appropriate balance
between precision and costs should be considered for further
clinical use.
A key issue of miRNA detection in stool is the selection of
endogenous control. Although several small RNA species are
recommended for normalising miRNA expression in tissues and
cell lines (Wong et al, 2007), the widely used RNU6B expression is
not correlated with total RNA concentration in stool (Link et al,
2010). In addition, RNU6B is rapidly degraded and the detection
rate was relatively low in stool specimens. As there is no consensus
on suitable control for stool testing, it is suggested that
quantification should be performed with equal amount of starting
total RNA or adopting other stably expressed small RNAs as
normaliser, such as the classical 18S rRNA control and miR-16.
It has been reported that the expression levels of several
miRNAs can distinguish healthy control and ulcerative colitis from
CRC, as well as to differentiate among CRC with different Dukes’
stages. miR-21, miR-106a, miR-96, miR-203, miR-20a, miR-326
and miR-92 showed a higher expression level in stool of CRC
patients with advanced Dukes’ stages, while miR-320, miR-126,
miR-484-5p, miR-143, miR-145, miR-16 and miR-125b exhibited
lower expression in stool of CRC patients with advanced Dukes’
stages. It is noteworthy that Ahmed et al (2009a) cannot provide a
sufficient statistical power for each miRNA because of small
sample size used in the study. Moreover, their conclusion was
challenged by other studies. Link et al (2010) reported that the
levels of stool miR-21 and miR-106a were significantly increased in
patients with CRC and adenoma compared with normal controls,
but were negatively associated with tumour stages. On the other
hand, the expression levels of miR-143 as well as miR-17, miR-622
and miR-654-3p were found to have no significant difference
between colorectal neoplasia and normal control.
On the basis of screening of 59 patients and 74 normal controls,
we previously reported that stool miR-92a and miR-21 levels were
significantly higher in CRC compared with normal controls. At a
cut-off value of 430 copies per ng of extracted stool RNA, miR-92a
had a sensitivity of 50% and a specificity of 80% towards CRC. At a
cut-off value of 820000 copies per ng, miR-21 had a sensitivity of
50% and a specificity of 83% (Table 1). However, stool miR-92a
cannot distinguish adenoma and CRC, or different CRC stages
(Wu et al, 2010). In the largest cohort to date, Koga et al (2010)
reported the stool miR-17-92 cluster and miR-135 significantly
increased in CRC patients, with sensitivities of 69.5 and 46.2%,
and specificities of 81.5 and 95.0%, respectively (Table 1).
In addition, the sensitivities of the stool miR-17-92 cluster and
miR-135 were lower for the proximal region tumour detection.
Although the expression level of miR-21 increased in cancer tissue,
stool miR-21 showed no difference between CRC patients and
healthy volunteers.
It has been postulated that tumour cells and most tumour
markers can be readily detected in stool at earlier stages of CRC
than in blood. Thus, stool miRNA testing has the advantage for
pre-cancerous lesion screening (Ahlquist, 2010). On the other
hand, colonocytes shed from proximal region will transit a longer
distance and will be more exposed to cytolytic agents, thus less
likely to be preserved and sampled. If this is a common
phenomenon for stool miRNA markers, right-sided CRC will have
less chance to be detected by this approach. Although the use of
stool miRNAs as biomarkers is still in its infancy and none of the
miRNA discussed above has progressed beyond the preclinical
stage, the available data indicated that higher specificity, sensitivity
and reproducibility can be achieved for stool miRNA detection.
Further studies of stool miRNA characterisation and validation are
needed for CRC diagnosis.
miRNAs AS PROGNOSTIC MARKERS FOR CRC
In spite of the improvement in surgical technique, CRC patients
who have an operable tumour will still have a high risk of
subsequent locoregional relapse. On the other hand, the clinical
responses to adjuvant therapy vary among individuals. Recently,
the utility of miRNA as prognostic markers for CRC has been
extensively studied.
Several preclinical and clinical studies have highlighted the
potential of miR-21 as a highly promising prognostic marker.
Slaby et al (2007) reported that miR-21 upregulation in CRC
patients were associated with lymph node positivity and develop-
ment of distant metastasis based on their study of 29 patients.
Later, a larger scale study using miRNA array was conducted with
two independent cohorts with different races and geographical
distributions. Schetter et al (2008) identified 37 aberrantly
expressed miRNA in CRC, among which 5 highly expressed
miRNA (miR-20a, miR-21, miR-106a, miR-181b and miR-203)
were associated with poor survival in the test cohort. Further
validation confirmed the statistically significant association
between poor prognosis and high tumour level of miR-21 in Asian
CRC patients. In addition, high miR-21 expression level was found
to be associated with poor response to adjuvant therapy and more
rapid recurrence in patients with stage III disease. Kulda et al
(2010) confirmed that higher miR-21 level in primary tumour was
correlated with shorter disease-free interval (DFI), but not with
overall survival (OS). Although significantly higher level of miR-21
was also found in liver metastasis of CRC, its level was not
associated with DFI or OS. miR-31 is another crucial factor for
tumour metastasis and it is dysregulated in both CRC cell lines and
tissues. Bandre ´s et al (2006) found that the expression level of
miR-31 was significantly increased in stage IV compared with
stage II CRC. Wang et al (2009) confirmed the association between
miR-31 level and pathological stages, including local invasion.
Numerous other miRNAs (Table 2) are also shown to have
potential predictive value for prognosis, but further large-scale
studies are needed for their validation.
It is known that microsatellite status is associated with CRC
disease course and response to adjuvant therapy. Lanza et al
(2007) first suggested a link between microsatellite status and
different miRNA profiles, and identified 14 differentially expressed
miRNA between microsatellite stable tumour (MSS) and micro-
satellite unstable tumour-high (MSI-H). Employing miRNA array
on 49 specimens from TNM stage II CRC patients, Schepeler et al
(2008) showed a signature consisting of 4 miRNAs (miR-142-3p,
miR-212, miR-151 and miR144) could significantly separate MSI
from MSS tumours, with 92% sensitivity and 81% specificity.
Furthermore, they reported that 17 miRNAs could separate the
MSS subtype according to the metastatic recurrence status,
resulting in 81% accuracy, 77% sensitivity and 83% specificity.
Among the 17 miRNAs, high levels of miR-320 and miR-498 were
associated with longer progression-free survival. Moreover, sub-
groups of MSI (MSI-high (MSI-H) and MSI-low (MSI-L)) could be
distinguished with miRNAs. Earle et al (2010) later reported that
upregulation of miR-92, let-7a and miR-145 were associated with
MSI-L status whereas increased level of miR-155, miR-223, miR-31
and miR-26b were correlated with MSI-H status.
miRNAs AS PREDICTIVE MARKERS FOR
TREATMENT OUTCOME IN CRC
Fluoropyrimidine-based adjuvant therapy is commonly used in
CRC treatment. Patients who respond to S-1, the fourth-generation
Fluoropyrimidine, showed lower levels of miR-181b and let-7g.
However, neither miR-181b nor let-7g was associated with survival
(Nakajima et al, 2006). Moreover, by induction G2 phase arrest
through downregulation of denticleless protein homolog in a p53-
dependent manner, miR-215 increased chemoresistance of
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cisplatin and doxorubicin (Song et al, 2010). Remarkably, although
miR-215 was downregulated in clinical colon cancer specimen,
high level of miR-215 was found in colon cancer stem cells.
Cetuximab, the monoclonal antibody that inhibits epidermal
growth factor receptor signal transduction, is used to treat
metastatic or advanced CRC with wild-type KRAS. Ragusa et al
(2010) found that miR-146b-3p and miR-486-5p were more
abundant in mutant KRAS patients compared with wild-type
ones. Moreover, they suggested that the downregulation of let-7b
and let-7e and upregulation of miR-17-3p were potential predictive
markers of cetuximab resistance.
Several miRNAs are also implicated in the modulation of
radiosensitivity. Svoboda et al (2008) reported that median levels
of miR-125b and miR-137 were upregulated in rectal cancer
patients after a short-course of capecitabine-based chemoradio-
therapy, and higher induction of miR-125b and miR-137 were
associated with worse response to the treatment. Moreover, Ahmed
et al (2009b) found different miRNA expression patterns of colon
cancer cell line HT29 treated with two clinical X-irradiation
modalities. Nonetheless, their clinical values remain unexplored.
miRNA-RELATED SINGLE-NUCLEOTIDE
POLYMORPHISMS INFLUENCED RISK OF SPORADIC
CRC AND THERAPY RESPONSE
The whole genome is constantly evolving and generates many
germ-line nucleotide changes known as single-nucleotide poly-
morphisms (SNPs). SNPs that fall into the protein coding sequence
may have a biological effect by changing the amino acid sequence
or yielding a premature stop code. Although SNPs residing in the
untranslated region (UTR) do not alter the function of the protein,
they may occasionally perturb the protein expression level and
may have pathogenic consequences (Yu et al, 2007). As a result of
the stringent sequence requirement of miRNA, it is speculated that
SNPs residing in miRNA-associated motifs in the 30 UTR, such as
the seed region and position 13–16, will potentially interfere with
the formation of miRNA::mRNA complex. It raises the possibility
that individuals with altered miRNA target site within tumour-
related genes are more prone to develop CRC. The initial study of
association between SNPs at miRNA-binding sites and CRC risk
was reported by Landi et al (2008). The selected 104 candidates are
well-known genes that are related to inflammation, prostaglandins
and thromboxane synthesis, obesity and insulin resistance. By
in silicon searching for the SNPs in 30 UTR and assessing the
variation of Gibbs energy between the alleles and validation in a
case–control study, they reported that both heterozygotes and
homozygotes of SNP (rs17281995) within CD86 showed a
statistically significant association with increased risk of CRC in
Caucasians (especially the risk of rectal cancer), and that the G4C
substitution would weaken the affinity of miR-337, miR-582 and
miR-200a* (Landi et al, 2008). Another SNP that less strongly
associated with CRC risk is rs1051690 within insulin receptor
(INSR), which would theoretically impact miR-612 and miR-618
(Landi et al, 2008) (Table 3). One more thing that should be
addressed is the predicted miRNAs may possibly be false-positive
errors, because the algorithm is updating and all the five miRNAs
predicted in Landi’s paper are not found in the latest miRNA
online databases. Thus, whether illegitimate miRNA target site can
cause higher CRC risk needs to be experimentally verified in the
future.
Ultraconserved region (UCR) encodes a class of non-coding
RNAs and their expression can be regulated by miRNA in vivo
(Calin et al, 2007). Previous studies indicated that SNPs at UCR
loci are related to cancer susceptibility (Yang et al, 2008). Wojcik
et al (2010) randomly selected and sequenced 28 UCRs in
Caucasians and identified 4 UCRs harboured sequence variations
in 35 CRC patients, but none of them existed in a cohort of 175
cancer-free control. The A4G substitution at position 90 of uc.276
in CRC patients would putatively disturb the interaction with
miR-214 and miR-887.
Single-nucleotide polymorphisms located within the miRNA
biogenesis machinery or the miRNA itself may also have possible
influences on clinical outcomes. Exportin 5 (XPO5) is responsible
for the miRNA::miRNA duplex cytoplasm translocation. Inacti-
vated XPO5 trapped many precursor miRNA that had potential
tumour-suppressor feature in the nucleus, and promoted cancer
growth in vitro and in vivo (Melo et al, 2010). Boni et al (2010)
discovered a trend of association between SNP (rs11077) in 30UTR
of XPO5 and disease control rate. It is not clear whether this SNP
influence protein level of XPO5 as well as precursor miRNA
shuttling. Lee et al (2010) reported that 23 SNPs (including
rs11077) in the functional regions of miRNA biogenesis machinery
did not influence survival of CRC patients. In addition, SNP
(rs1834306) in 50UTR of pri-miR-100 was weakly associated with
CRC progression while C4T substitution (rs7372209) in 50UTR of
pri-miR-26a-1 was significantly associated with disease progres-
Table 2 miRNAs as potential prognostic and predictive markers for CRC
miRNA Dysregulation
a Clinical-related phenotypes Reference
let-7g Upregulated in CRC Higher level associated with poor S-1 response Nakajima et al, 2006
miR-18a Upregulated in CRC Higher level associated with poor overall survival Motoyama et al, 2009
miR-21 Upregulated in adenoma, CRC, and
liver metastasis tissue
Higher level associated with lymph node positivity, metastasis;
poor survival, poor therapeutic outcomes, rapid recurrence;
shorter disease-free interval
Slaby et al, 2007; Schetter et al, 2008;
Kulda et al, 2010
miR-31 Upregulated in CRC Higher level associated with higher TNM stages and local invasion Bandre ´s et al, 2006; Slaby et al, 2007;
Wang et al, 2009
miR-106a Upregulated in colon cancer Higher level associated with longer disease-free survival
and overall survival
Dı ´az et al, 2008; Schetter et al, 2008
miR-143 Downregulated in colon cancer and
liver metastasis tissue
Lower level associated with larger tumour size and longer
disease-free interval
Slaby et al, 2007; Motoyama et al, 2009;
Wang et al, 2009; Kulda et al, 2010;
miR-145 Downregulated in CRC Lower level associated with large tumour size; related
with tumour location
Slaby et al, 2007; Motoyama et al, 2009
Wang et al, 2009;
miR-181b Upregulated in CRC Higher level associated with poor S-1 response Nakajima et al, 2006
miR-320 Downregulated in MSS tumour Lower level associated with shorter progression-free survival Schepeler et al, 2008
miR-498 Downregulated in MSS tumour Lower level associated with shorter progression-free survival Schepeler et al, 2008
Abbreviations: CRC¼colorectal cancer; miRNA¼microRNA; MSS¼microsatellite stable tumour; TNM¼tumour-node-metastasis.
aUp- or downregulation is stated as
miRNA expression relative to normal colon tissue, or MSS relative to MSI.
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located in miRNA precursors, with inclusion of rs1834306 and
rs7372209, did not influence the OS rate in a study of 426 surgically
treated Korea CRC patients (Lee et al, 2010).
Single-nucleotide polymorphisms and their mechanisms related
to CRC progression remain to be investigated. Since SNPs in the
miRNA-binding motifs are sometimes deleterious, natural selec-
tion keeps the SNP density in conserved seed region at lower level
than expected, approximately 0.50 SNP per kb (Chen and
Rajewsky, 2006). Nevertheless, genome-wide screening for
miRNA-related SNPs and understanding of their biological
relevance can make further advances in the evaluation of
individual CRC susceptibility, expending the list of CRC-associated
genes, and ultimately help to develop patient-tailored medicine.
FUTURE PERSPECTIVE
Genome-wide searching can help identify many oncogenic and
tumour-suppressing miRNAs, which are potential therapeutic
targets for CRC treatment. Theoretically, the downregulated
miRNAs can be replaced by chemically synthesised mimics.
Overexpressed miRNAs can also be targeted by anti-miRNA
oligonucleotides. Recently, Idogawa et al (2009) reported that
adenovirus mediated cocistronic expression of the p53 protein and
artificial miRNA that targeted p21 increased the chemosensitivity
of infected CRC cells. However, without fully understanding their
biological functions, manipulation of miRNA can potentially
induce severe side-effects as miRNA will influence a spectrum of
genes. In addition, the technique of target-specific delivery of
miRNA is immature. Many issues must be addressed before the
preclinical findings can be translated into clinical benefits.
In conclusion, those studies mentioned above highlight the
potential value of miRNAs in CRC diagnosis, prognosis and
susceptibility. Further large-scale evaluation in multiple indepen-
dent cohorts is indispensable for determining their realistic
expectation.
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rs11077 30UTR of XPO5 A/C — Weak associated with DCR; not associated with survival Boni et al (2010);
Lee et al (2010)
rs7372209 50UTR of pri-miR-26a-1 C/T miR-26a-1 Significantly associated with ORR and TTP; not
associated with survival
Boni et al (2010);
Lee et al (2010)
rs1834306 50UTR of pri-miR-100 C/T miR-100 Weak associated with TTP; not associated with survival Boni et al (2010);
Lee et al (2010)
Abbreviations: CRC¼colorectal cancer; DCR¼disease control rate; ORR¼overall response rate; M¼major allele; m¼minor allele; miRNA¼microRNA; SNP¼single-
nucleotide polymorphism; TTP¼time to progression; UTR¼untranslated region.
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